Arcus Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Arcus Biosciences, Inc. (RCUS) on June 27, 2023. The filing reports the entry into a material definitive agreement with Gilead Sciences, Inc. regarding the purchase of Arcus common stock.
Key Financial Metrics and Transaction Details
The filing details a specific equity transaction rather than periodic financial performance metrics such as revenue or operating cash flow.
- Transaction Type: Sale of unregistered common stock to Gilead Sciences, Inc.
- Shares Sold: 1,010,000 shares.
- Purchase Price: $19.26 per share.
- Total Proceeds: Approximately $19.45 million (calculated as 1,010,000 shares * $19.26).
- Regulatory Basis: Sold pursuant to Section 4(a)(2) of the Securities Act of 1933 to an accredited investor.
Material Changes and Agreement Terms
The transaction involves a Second Amended and Restated Common Stock Purchase Agreement (A&R Purchase Agreement) which amends and restates the agreement originally entered into on January 31, 2021.
- Option to Purchase: Gilead retains an option to purchase additional shares from Arcus from time to time until July 13, 2025.
- Maximum Ownership: The option allows Gilead to purchase up to a maximum of 35% of Arcus's then-outstanding common stock.
- Closing Conditions: The transaction is subject to customary closing conditions.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the brief description is qualified by the full agreement text. The full agreement is scheduled to be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ended June 30, 2023.
Key Facts for Investor Verification
- Verify the closing of the transaction and receipt of proceeds by reviewing the subsequent Form 10-Q.
- Review the full text of the Second Amended and Restated Common Stock Purchase Agreement for specific closing conditions and covenants.
- Monitor future filings for any exercise of Gilead's option to purchase additional shares up to the 35% cap.
- Confirm the impact of this equity issuance on Arcus's total outstanding share count and potential dilution.